Skip to main navigation

Investor Relations

Overview
Stock
Stock Quote & Chart Analyst Coverage
News & Events
News Releases Investor Calendar Presentations
Financials
SEC Filings Quarterly Results
Governance
Governance Highlights Committee Composition
Resources
Investor FAQs Email Alerts Contact IR

News Releases

Year

Jan 26, 2022

Aligos Therapeutics Begins Dosing in Chronic Hepatitis B Patients in its Phase 1 Antisense Oligonucleotide Study (ALG-020572-401)

Administration of single ascending doses up to 480 mg in healthy volunteers nearly complete First chronic hepatitis B patient dosed in initial cohort, each of which will be administered 7 subcutaneous doses over 29 days SOUTH SAN FRANCISCO, Calif., Jan.

Jan 11, 2022

Aligos Therapeutics Expands Collaboration with Merck to Develop Oligonucleotide Therapies for NASH

SOUTH SAN FRANCISCO, Calif., Jan. 11, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that it has expanded its ongoing

Jan 06, 2022

Aligos Halting Further Development of STOPS™ Drug Candidate, ALG-010133

Phase 1 data at projected efficacious dose (400 mg) indicate insufficient activity against hepatitis B virus to justify further development SOUTH SAN FRANCISCO, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on

Shareholder Tools

Print Page
Email Alerts
RSS
Investor FAQs

© Aligos Therapeutics 2022